RapidAI receives FDA 510(k) to identify potential pulmonary embolism
The Rapid PE Triage& Notification tool analyzes CT pulmonary angiograms to find potential cases and alert care teams. (Source: mobihealthnews)
Source: mobihealthnews - May 24, 2022 Category: Information Technology Source Type: news
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
Post-Pulmonary Embolism Impairment Frequent, Follow-Up Urged After Acute PE Post-Pulmonary Embolism Impairment Frequent, Follow-Up Urged After Acute PE
In a large study of patients with acute pulmonary embolism, chronic thromboembolic pulmonary hypertension was rare, but post-pulmonary embolism impairment was not.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - May 19, 2022 Category: Intensive Care Tags: Cardiology News Source Type: news
Magneto Thrombectomy Solutions Announces Successful First-in-Human Results for Treatment of Pulmonary Embolism (PE)
The eTrieve catheter for removing blood clots, based on electric fields, met safety and feasibility endpoints
Data, showing significant reduction RV/LV ratio and alleviation of PE associated symptoms, presented at Biomed Israel 2022
OR YEHUDA, Israe... Devices, Interventional Magneto Thrombectomy Solutions, eTrieve catheter, pulmonary embolism (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 10, 2022 Category: Pharmaceuticals Source Type: news
Use of V/Q scans dropped during COVID-19 pandemic
Nuclear medicine ventilation/perfusion scintigraphy (V/Q) dropped significantl...Read more on AuntMinnie.comRelated Reading:
Are ventilation scans needed in pulmonary embolism assessments?
SNMMI issues new guidelines on V/Q scans
SNMMI urges fast-track review of Technegas for V/Q scans
SNMMI updates ventilation study guidance
CTA still most common modality for PE diagnosis (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 4, 2022 Category: Radiology Source Type: news
Cardiovascular Mortality Down Among Dialysis Patients
Greater declines seen for myocardial infarction, stroke, and pulmonary embolism among dialysis patients than general population (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - April 19, 2022 Category: Respiratory Medicine Tags: Cardiology, Endocrinology, Family Medicine, Internal Medicine, Nephrology, Pulmonology, Journal, Source Type: news
COVID-19 Linked to Increased Risk for DVT, PE, Bleeding
FRIDAY, April 8, 2022 -- COVID-19 is associated with an increased risk for deep vein thrombosis, pulmonary embolism, and bleeding, according to a study published online April 6 in The BMJ.
Ioannis Katsoularis, M.D., from Umeå University in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 8, 2022 Category: Pharmaceuticals Source Type: news
Post-COVID Risk for Blood Clot Lasts at Least 6 Months
New findings suggest COVID-19 is an independent risk factor for deep vein thrombosis, pulmonary embolism and bleeding. (Source: WebMD Health)
Source: WebMD Health - April 7, 2022 Category: Consumer Health News Source Type: news
Covid linked to 33-fold increase in risk of pulmonary embolism
Infection with virus also associated with fivefold increase in risk of deep vein thrombosis, data suggestsCatching Covid is associated with a fivefold increase in the risk of deep vein thrombosis (DVT) and a 33-fold increase in risk of a potentially fatal blood clot on the lung in the 30 days after becoming infected, data suggests.The findings,published in the British Medical Journal on Thursday, could help explain a doubling in the incidence of, and deaths from, blood clots in England since the start of the pandemic compared with the same periods in 2018 and 2019.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - April 6, 2022 Category: Science Authors: Linda Geddes Tags: Coronavirus World news Science Infectious diseases Microbiology Medical research Health Society Source Type: news
Janssen Announces Health Canada Approval of RYBREVANT ® (amivantamab), the First and Only Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Toronto, ON, April 4, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) approving RYBREVANT® (amivantamab), a fully-human, bispecific antibody, for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.[i] Health Canada NOC/c is granted to promising new therapies for patients diagnosed with serious, life-threate...
Source: Johnson and Johnson - April 4, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19, JAMA Network
This study suggests that early aspirin use may be associated with lower odds of in-hospital mortality among hospitalized patients with moderate COVID-19; these findings warrant further study in a randomized clinical trial that includes diverse patients with cardiovascular comorbidities. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 31, 2022 Category: Consumer Health News Source Type: news
How Their Son ’s Death Drove His Parents to Find an Alternative to Tradition
To John and Susan Garretson, the thought of cremating their son in the conventional way was almost as excruciating as the memory of his death.
On March 20, 2021, a police officer in Peachtree City, Ga., knocked on the Garretsons’ door to say their only child, 16-year-old Brighton Garretson, had been killed in a car crash. Brighton, a high school sophomore, had been a passenger in his friend’s newly purchased Corvette for less than a minute before the sports car collided with another vehicle and went up in flames. The occupants of the other vehicle survived, but Brighton and his 19-year-old friend died instantly...
Source: TIME: Science - March 7, 2022 Category: Science Authors: Melissa Chan Tags: Uncategorized COVID-19 Evergreen healthscienceclimate nationpod Source Type: news
Mesothelioma Clinical Trial Matches Treatment to Genetic Profiles
This study met its primary endpoint, showing promising clinical activity of abemaciclib in patients with p16ink4A-negative mesothelioma who were previously treated with chemotherapy,” the authors concluded. “[This therapy] warrants further investigation in a randomized study as targeted stratified therapy.”
Some patients may have genes that allow a particular response to a drug, such as abemaciclib, but there is still potential to find targets beneficial to other patients.
The researchers are interested in adding additional therapy options for patients as the clinical trial continues. Depending on their genetic...
Source: Asbestos and Mesothelioma News - February 28, 2022 Category: Environmental Health Authors: Fran Mannino Source Type: news
POCUS can rule out PE in critical COVID-19 patients
Point-of-care ultrasound (POCUS) can help rule out pulmonary embolism (PE) i...Read more on AuntMinnie.comRelated Reading:
POCUS on par with x-ray for COVID-19 diagnosis, management
Should breast ultrasound scans after COVID vaccines be postponed?
POCUS good for localizing catheters in newborn patients
POCUS a good tool for detecting coins swallowed by kids
POCUS making waves, but questions remain (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 3, 2022 Category: Radiology Source Type: news
